Monday September 14, 1200-1300 (UTC)

Joseph Ciccolini, Aix Marseille Université U105, Institut Paoli Calmettes & APHM
D.J.A.R Moes, Leiden University Medical Center, The Netherlands
Etienne Chatelut, Institut Universitaire du Cancer-Toulouse, France
Jeroen J.M.A. Hendrikx, The Netherlands Cancer Institute – Amsterdam, The Netherlands

Learning Objectives: At the end of this session participants will be able to:
- Describe the current challenges and pitfalls of TDM in Oncology.
- Discuss pharmacokinetic-pharmacodynamic relationships of Mab in Onco-Hematology.
- Formulate their own opinion on this pending issue (i.e., TDM of Mab in Oncology).

Question Title

* 1. This session overall

  Disagree Neutral Agree Strongly Agree
Sufficient time was allowed for audience participation/active learning
The session was free from commercial bias

Question Title

* 2. Overall, I would rate this symposium as:

Question Title

* 3. Speaker: Joseph Ciccolini

  Fair Good Very Good Outstanding
Knowledgeable, organized and effective
Educational content/Relevance to practice
Balanced and unbiased

Question Title

* 4. Speaker: D.J.A.R Moes

  Fair Good Very Good Outstanding
Knowledgeable, organized and effective
Educational content/Relevance to practice
Balanced and unbiased

Question Title

* 5. Speaker: Etienne Chatelut

  Fair Good Very Good Outstanding
Knowledgeable, organized and effective
Educational content/Relevance to practice
Balanced and unbiased

Question Title

* 6. Speaker: Jeroen J.M.A. Hendrikx

  Fair Good Very Good Outstanding
Knowledgeable, organized and effective
Educational content/Relevance to practice
Balanced and unbiased

Question Title

* 7. As a result of attending this session, I am planning to:

Question Title

* 8. Please explain any changes you plan to make or personal learning projects you will pursue as a result of this session:

Question Title

* 9. What topics would you like to be addressed at future conferences to keep you up to date in your profession?

T